NEW YORK – Digital pathology firm Gestalt said Wednesday that it has formed a partnership with dermatology medical technology firm Primaa to integrate that firm’s skin cancer test with Gestalt's software platform.
The deal offers the use of Paris-based Primaa's artificial intelligence-developed algorithms for the detection and quantification of tumor biomarkers in skin tissue samples with Spokane, Washington-based Gestalt's PathFlow software platform, which is used to perform laboratory-developed tests in the US and is CE-marked under the EU's In Vitro Diagnostic Regulation. The algorithms are used to identify lesions including melanoma, squamous cell carcinoma, and basal cell carcinoma with measurements of lesion dimensions and margins. They can also be used to detect perineural invasions and mitosis objects within melanoma as well as prioritize high-risk cases for review.
Financial and other terms of the deal were not disclosed.
"This partnership represents a pivotal advancement in enhancing workflow efficiency and delivering superior patient care related to skin cancer," Gestalt Chief Operating Officer and Chief Strategy Officer Lisa-Jean Clifford said in a statement.